Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

75%

6 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

6(75.0%)

Phase 2

2(25.0%)

8Total

Phase 3(6)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07436611Phase 2Not Yet Recruiting

Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains

Role: lead

NCT07225634Phase 3Not Yet Recruiting

A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain

Role: lead

NCT07225140Phase 3Not Yet Recruiting

A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery

Role: lead

NCT04005755Phase 3Completed

Maxigesic® IV Phase 3 Exposure Study

Role: lead

NCT02689063Phase 3Completed

Maxigesic IV Phase 3 Bunionectomy Study

Role: lead

NCT01420653Phase 3Completed

Maxigesic 325 Acute Dental Pain Study

Role: lead

NCT01420666Phase 3Withdrawn

Maxi-Analgesic Osteoarthritis (OA) Study

Role: lead

NCT01104844Phase 2Withdrawn

Maxi-Analgesic Phase 2 Study to Compare the Analgesic Effects in Different Dosing Groups to Treat Teeth Extraction Pain

Role: lead

All 8 trials loaded